The offices and manufacturing facility of Emergent Biosolutions, which manufactured vaccines for AstraZeneca and Johnson & Johnson, are seen through a security fence on February 8 in Baltimore, Maryland. Michael Robinson Chavez/The Washington Post/Getty Images

The federal government has moved to stop any further risk of contamination at a Baltimore contract vaccine manufacturer where 15 million potential doses of Johnson & Johnson vaccine were spoiled last month, telling rival drugmaker AstraZeneca it must move its production from the plant and find somewhere else to make its vaccine.

The Emergent BioSolutions plant in Baltimore was making coronavirus vaccines under contract to both Johnson & Johnson and AstraZeneca. Last month, a batch of Johnson & Johnson “drug product” failed quality control and was taken out of production, both J&J and Emergent have said.

The federal government has directed Johnson & Johnson to fully take over its vaccine production at the plant, an administration official told CNN Saturday. The company confirmed it was taking tighter control of the production process.

The Emergent BioSolutions plant, which had been making doses of both Johnson & Johnson’s vaccine as well as a vaccine made for AstraZeneca, will now only produce J&J vaccines, the official said. The Health and Human Services Department has directed that the AstraZeneca vaccine will now be produced at another plant, although the official did not specify where.

“Johnson & Johnson is assuming full responsibility regarding the manufacturing of drug substance for its COVID-19 vaccine at the Emergent BioSolutions Inc. Bayview facility,” the company said in a statement emailed to CNN.

Read more here.


Please enter your comment!
Please enter your name here